A message to our global community
The effects of this pandemic are undeniable. During these unprecedented times, AGC Biologics is committed to keeping our employees safe and working with our partners in the pharmaceutical industry to help produce lifesaving products for communities and patients worldwide.
Collaborating with our partners in the fight against COVID-19
The world as we know it has changed. With COVID-19, we are no longer living a normal life. We must learn new ways to live. New ways to work. New ways to cope.
AGC Biologics is here and working harder than ever. We are collaborating with our partners to help them bring therapeutics and vaccines to the world, in the fight against this global pandemic.
News Stories on our COVID-19 Partnerships
Novavax, Inc. Expands Partnership with AGC Biologics to Manufacture Critical Component of Novel COVID-19 Vaccine from its Seattle Facility
Press Release | August 10, 2020
Molecular Partners AG Joins Forces with AGC Biologics to Develop and Produce a Unique, Tri-Specific Approach to Target SARS-CoV-2
Press Release | July 9, 2020
Saiba AG Selects AGC Biologics to Manufacture a SARS-CoV-2 Vaccine to Protect Against COVID-19
Press Release | June 16, 2020
Novavax, Inc. Partners with AGC Biologics to Manufacture Critical Component of Novel COVID-19 Vaccine
Press Release | June 3, 2020
Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)
Press Release | May 20, 2020
AdaptVac Partners with AGC Biologics to Develop and Produce COVID-19 Vaccine
Press Release | April 23, 2020
CytoDyn Inc. Partnership with AGC Biologics Featured on Local News Stations
Watch the KIRO-7 news story
Watch the KOIN-6 news story
Videos | April 2020